Filing Analysis
SBC Medical Group Holdings Inc. filed an 8-K to announce its second quarter 2026 financial results for the period ended June 30, 2026.
📋 Key Facts
- Reported quarterly earnings results via press release dated August 13, 2026.
- Released '2Q 2026 Investor Presentation' and '2Q 2026 Group Overview' on the company website.
- The filing includes an exhibit (99.1) containing the financial results press release.
SBC Medical Group Holdings Inc. has received a notice from Nasdaq regarding non-compliance with independence rules for its Board and Audit Committee following the departure of director Mike Sayama. The company has been granted a cure period to regain compliance by either its next annual meeting or July 9, 2027.
🚩 Red Flags
- Nasdaq non-compliance notice regarding board independence.
- Significant governance changes: Shareholders approved amendments to allow director removal without cause (Proposal 4) and officer exculpation (Proposal 6).
- Board size is currently below the required threshold for committee composition due to recent departures.
📋 Key Facts
- Nasdaq issued notice on July 10, 2026, stating non-compliance with Listing Rule 5605 regarding independent director and audit committee requirements.
- The departure of Mike Sayama left the Board with only two independent directors (out of four) and the Audit Committee with only two independent members.
- A cure period has been granted until July 9, 2027, or the next annual meeting if held before January 5, 2027.
- The company is actively searching for a fifth independent director to increase Board size and restore committee compliance.
- Stockholders approved several charter amendments at the Annual Meeting on July 8, 2026, including removing 'for cause' removal requirements for directors and providing officer exculpation.
On May 14, 2026, independent director Mike Sayama notified SBC Medical Group Holdings Inc that he will not seek re-election at the 2026 Annual Meeting of Stockholders. The company will temporarily reduce its board size to four members while searching for a replacement independent director.
🚩 Red Flags
- Temporary reduction in board size and committee membership (audit, compensation, and nominating committees) until a replacement is found.
📋 Key Facts
- Independent director Mike Sayama notified the company on May 14, 2026, that he will not seek re-election at the 2026 Annual Meeting of Stockholders.
- The board of directors has reduced its size to four members effective immediately prior to the 2026 AGM.
- The company is actively searching for a fifth independent director to restore the board size to five and fill committee vacancies.
- Mr. Sayama's departure was not due to any disagreement with the company, management, or the board.
SBC Medical Group Holdings Inc. announced its financial results for the first quarter ended March 31, 2026, and released an updated investor presentation. The filing serves as a routine quarterly update for investors regarding the company's operational performance.
📋 Key Facts
- Announced Q1 2026 financial results on May 14, 2026.
- Released an investor presentation titled '1Q 2026 Investor Presentation' on the company's website.
- The filing includes Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure).
- Yuya Yoshida serves as both Chief Financial Officer and Chief Operating Officer.
SBC Medical Group Holdings announced a secondary underwritten offering of 3,100,000 shares of common stock by its CEO and Chairman, Dr. Yoshiyuki Aikawa. The company received no proceeds from the transaction, which closed on April 21, 2026.
🚩 Red Flags
- Significant insider liquidation: The CEO and Chairman is selling a large block of shares (3.1M+).
- Zero capital benefit: The company receives no proceeds to fund operations or growth despite the market activity.
- Potential for significant downward price pressure due to the secondary market supply increase.
📋 Key Facts
- Underwriting agreement signed April 19, 2026, with Maxim Group LLC as the representative.
- The selling stockholder is Dr. Yoshiyuki Aikawa, the Company’s CEO and Chairman of the board.
- 3,100,000 shares were sold, with an additional 45-day option for underwriters to purchase 465,000 more shares from the CEO.
- The company did not sell any shares and received $0 in proceeds from the offering.
- The offering was conducted under a Registration Statement on Form S-3 filed on December 29, 2025.
SBC Medical Group Holdings reported its Q4 and full-year 2025 financial results on March 27, 2026. The filing also includes an investor presentation and updates regarding the company's business strategy and capital policy.
🚩 Red Flags
- Multiple 8-K items (2.02, 7.01, 8.01) triggered in a single filing, which can indicate complex corporate developments occurring simultaneously with earnings.
📋 Key Facts
- Announced fourth quarter and full year 2025 financial results on March 27, 2026.
- Released an investor presentation titled 'Group Business' providing a business overview.
- Announced updates to business strategy and capital policy under Item 8.01.
- The report was signed by Yuya Yoshida, who serves as both CFO and COO.
- Information was disseminated via press release (Exhibit 99.1) and website updates.
SBC Medical Group Holdings announced the completion of a strategic minority equity investment in OrangeTwist, a U.S.-based MedSpa chain. The deal includes a structured collaboration framework with institutional shareholders Hildred Capital and Athyrium Capital to facilitate expansion into the U.S. medical aesthetics market.
🚩 Red Flags
- None identified in this filing.
📋 Key Facts
- Completed a strategic minority equity investment in OrangeTwist (U.S. MedSpa chain) on January 5, 2026.
- Entered into a structured collaboration framework with institutional shareholders Hildred Capital and Athyrium Capital.
- The transaction is part of a multi-phase global expansion strategy targeting aesthetic medicine and regenerative medicine.
- The company aims to leverage cross-border clinical and operational synergies between the U.S. and Asia.
SBC Medical Group Holdings Inc. announced an updated capital strategy, which includes the authorization of a $20.0 million share repurchase program and the effectiveness of its Form S-3 registration statement.
📋 Key Facts
- Board of Directors authorized a $20.0 million share repurchase program.
- Repurchases may occur via open market transactions, Rule 10b5-1 trading plans, or privately negotiated transactions.
- The repurchase program is scheduled to terminate on December 31, 2026.
- Funding for the program will come from surplus cash and future free cash flow.
- Form S-3 registration statement has been declared effective.
SBC Medical Group Holdings Inc. announced the successful results of a tender offer for Waqoo, Inc., a Japanese company listed on the Tokyo Stock Exchange Growth Market. The acquisition will result in SBCMG holding over 50% ownership of Waqoo following additional off-market share transfers.
🚩 Red Flags
- Oversubscription of tender offer indicates high demand/interest but also implies the company may not have been able to capture all tendered shares due to volume caps.
📋 Key Facts
- Tender Offeror: SBC Medical Group Co., Ltd. (SBCMG)
- Target Company: Waqoo, Inc. (TSE Growth: 4937)
- Offer Price: ¥1,900 per share
- Total shares tendered: 637,817 shares (exceeding the maximum planned volume of 575,000)
- SBCMG will purchase 575,052 shares on a pro rata basis
- Ownership ratio via tender offer: 24.93%
- Expected total ownership post-settlement (including off-market transfer): >50%
- Settlement Date: December 19, 2025
SBC Medical Group Holdings Inc. filed an 8-K to announce its third quarter 2025 financial results and provide an updated investor presentation.
📋 Key Facts
- The filing announces the release of financial results for the quarter ended September 30, 2025.
- An investor presentation regarding the Q3 2025 results was posted to the company website on November 13, 2025.
- The report includes Exhibit 99.1 (Press Release) and Exhibit 99.2 (Investor Presentation).
SBC Medical Group Holdings Inc. announced a plan to acquire Waqoo, Inc., a Tokyo Stock Exchange-listed company, through a combination of a tender offer and an off-market transfer from the CEO.
🚩 Red Flags
- Related-party transaction: The CEO is transferring his 26.58% stake in Waqoo directly to the Company's subsidiary.
- Concentrated ownership/Control shift: The acquisition structure relies heavily on an off-market transfer from a key executive.
📋 Key Facts
- The Company's subsidiary (SBCMG) will launch a tender offer for up to 575,000 shares of Waqoo, Inc. starting November 14, 2025.
- The Tender Offer is scheduled to run through December 12, 2025, with settlement expected on December 19, 2025.
- SBCMG will acquire 989,802 shares of Waqoo from CEO Dr. Yoshiyuki Aikawa via an off-market transfer agreement dated November 13, 2025.
- Post-transaction, the Company intends for Waqoo to become a consolidated subsidiary.
- The acquisition will involve both existing corporate holdings (9.49%) and significant insider holdings (26.58%).
SBC Medical Group Holdings Inc. filed an 8-K to announce its second quarter 2025 financial results and provided an updated investor presentation.
📋 Key Facts
- The filing reports results for the fiscal quarter ended June 30, 2025.
- An investor presentation was posted to the company's IR website on August 13, 2025.
- The report includes Exhibit 99.1 (Press Release) and Exhibit 99.2 (Investor Presentation).
SBC Medical Group Holdings Inc. announced the acquisition of MB career lounge, Co., Ltd., a Japanese provider of management support services for medical institutions, via a cash-based share purchase transaction.
📋 Key Facts
- Acquisition target: MB career lounge, Co., Ltd.
- Target business model: Management support services (consulting, training, and HR solutions) for medical institutions in Japan.
- Transaction structure: Share purchase transaction for cash consideration.
- Filing date: July 17, 2025.
SBC Medical Group Holdings Inc. announced its inclusion in the Russell 3000® Index, effective June 30, 2025. This is a non-material regulatory disclosure under Item 7.01 regarding index reconstitution.
📋 Key Facts
- Inclusion in the Russell 3000® Index announced on June 27, 2025.
- Effective date of inclusion: After U.S. market opens on June 30, 2025.
- Part of the 2025 Russell indexes reconstitution.
SBC Medical Group Holdings Inc. held its 2025 Annual Meeting of Stockholders on June 13, 2025, where stockholders approved a significant amendment to the Certificate of Incorporation. The primary outcome was the declassification of the Board of Directors, transitioning the company from staggered terms to annual elections starting in 2026.
🚩 Red Flags
- Board declassification: While often seen as a governance positive, in micro-cap contexts, it can sometimes be a precursor to rapid management turnover or shifts in control.
📋 Key Facts
- Annual Meeting held on June 13, 2025.
- Stockholders approved Proposal 3: Amendment and restatement of the Certificate of Incorporation to declassify the Board of Directors.
- Current directors' terms will now end at the 2026 annual meeting instead of their original staggered expiration dates.
- Ratification of MaloneBailey, LLP as independent registered public accounting firm for fiscal year ending Dec 31, 2025.
- Quorum was met with 92,710,439 shares represented out of 103,611,251 outstanding shares.
SBC Medical Group Holdings announced its Q1 2025 financial results and a $5 million share repurchase program. Notably, the company disclosed it is reviewing the acquisition of Risenet Co., Ltd., a company whose shares are currently held entirely by the Company's CEO, Yoshiyuki Aikawa.
🚩 Red Flags
- Related-party transaction: The target company (Risenet Co., Ltd.) is 100% owned by the Company's CEO, Yoshiyuki Aikawa.
- Potential conflict of interest regarding the acquisition terms and valuation of Risenet.
📋 Key Facts
- Announced Q1 2025 financial results for the quarter ended March 31, 2025.
- Board approved a share repurchase program with a maximum aggregate amount of $5 million.
- Repurchase implementation period: May 20, 2025 – May 20, 2026.
- Funding for repurchases to come from surplus cash and future free cash flow.
- Company is reviewing the acquisition of Risenet Co., Ltd.
SBC Medical Group Holdings Inc. announced a management reshuffle effective April 10, 2025. Miki Shimizu will transition to Chief Strategy Officer, replacing Akira Komatsu, who will move to a subsidiary role in Japan.
📋 Key Facts
- Effective date of management change: April 10, 2025.
- Miki Shimizu is appointed as the new Chief Strategy Officer.
- Akira Komatsu is transitioning from Chief Strategy Officer to Chief of the Group Representative Office for SBC Medical Group Co., Ltd. (Japan).
- The company is an emerging growth company.
SBC Medical Group Holdings Inc. filed an 8-K to announce its financial results for the fourth quarter and full year ended December 31, 2024. The filing includes a press release and an investor presentation detailing the company's performance.
📋 Key Facts
- Report date: March 28, 2025
- Reporting period: Quarter ended December 31, 2024, and Full Year 2024
- The filing includes Exhibit 99.1 (Press Release) and Exhibit 99.2 (Investor Presentation)
- Company is an emerging growth company
SBC Medical Group Holdings Inc. announced via a press release that it has decided to purchase Bitcoin (BTC). This disclosure is made under Item 7.01 (Regulation FD Disclosure) and does not constitute a material change in business operations or financial structure.
🚩 Red Flags
- Potential for increased volatility due to exposure to highly volatile digital assets (Bitcoin).
📋 Key Facts
- Company issued a press release on February 12, 2025, regarding the purchase of Bitcoin (BTC).
- The disclosure is filed under Item 7.01 (Regulation FD Disclosure) rather than a material definitive agreement.
- The filing was signed by CFO Ryoji Murata on February 18, 2025.
SBC Medical Group Holdings Inc. is divesting two subsidiaries, Kijima and Skynet, to entities owned by its CEO, Dr. Yoshiyuki Aikawa. The company states the move is intended to refocus on its core medical business.
🚩 Red Flags
- Related-party transaction: The CEO is the direct purchaser of two subsidiaries.
- Asset divestiture at nominal/immaterial value: Selling assets for little to no consideration can be a method of shifting value away from public shareholders to insiders.
- Insolvency mention: One of the divested entities (Kijima) is noted as being insolvent.
📋 Key Facts
- On December 17, 2024, SBC Medical entered into agreements to sell all shares of subsidiaries SBC Kijimadaira Resort Co., Ltd. (Kijima) and Skynet Academy Co., Ltd. (Skynet).
- The buyer is Dr. Yoshiyuki Aikawa, the Company's Director, Chairman, and CEO.
- Kijima operates a ski resort/hotel management business; Skynet operates an aircraft pilot training business.
- Kijima was valued at a nominal price due to insolvency.
- Skynet was valued at an immaterial price via discounted cashflow method.
- Transactions are expected to close in December 2024.
SBC Medical Group Holdings Inc. filed an 8-K to announce its third quarter 2024 financial results and provide an investor presentation.
📋 Key Facts
- Reporting period: Quarter ended September 30, 2024.
- Filing date: November 13, 2024.
- The company released a press release (Exhibit 99.1) and an investor presentation (Exhibit 99.2) regarding financial highlights.
SBC Medical Group Holdings Inc. has successfully consummated a business combination with Pono Capital Two, Inc., transitioning from a SPAC structure to an operating entity via merger. The transaction involves the completion of a long-delayed merger process that had undergone multiple amendments and extensions.
🚩 Red Flags
- Extensive history of delays: The merger agreement underwent multiple extensions (Amendment No. 1 through Amendment No. 4) to push the 'Outside Date' from December 2023 to September 2024.
- Significant reduction in valuation/consideration: Merger consideration was reduced from $1.2 billion to $1.0 billion per Amendment No. 1.
- Complex restructuring: The target company underwent a corporate restructuring during the due diligence period, removing 'Medical Corporations' from the scope of the merger.
📋 Key Facts
- The Business Combination was completed on September 17, 2024.
- Pono Capital Two, Inc. changed its name to SBC Medical Group Holdings Incorporated following the merger.
- SBC Medical Group, Inc. (the former target) is now a wholly-owned subsidiary of Pono.
- The original Merger Agreement was dated January 31, 2023, and has undergone at least four significant amendments.
- The merger consideration calculation involved complex adjustments based on Net Working Capital and indebtedness.
Pono Capital Two, Inc. (a SPAC) successfully held a special meeting of stockholders on August 23, 2024, where shareholders approved the business combination with SBC Medical Group Holdings Incorporated. The company expects to close the merger in the coming days and will subsequently change its name to SBC Medical Group Holdings Incorporated.
🚩 Red Flags
- Significant dilution potential: Proposal 7 approved the issuance of up to 100,000,000 new shares for Nasdaq compliance, which is a massive increase relative to current voting shares.
- High equity incentive pool: 15% of fully diluted capital (approx. 15M shares) allocated to the new incentive plan.
📋 Key Facts
- Special Meeting held on August 23, 2024, with 68.45% of total outstanding shares voted (3,570,438 shares).
- Proposal 1 (Business Combination) passed: Approved the merger of SBC Medical Group Holdings Inc. into Pono.
- Proposal 2 (Name Change) passed: Company to be renamed 'SBC Medical Group Holdings Incorporated'.
- Proposal 5 (Director Election) passed: Five directors elected including Yoshiyuki Aikawa, Yuya Yoshida, Ken Edahiro, Mike Sayama, and Fumitoshi Fujiwara.
- Proposal 6 (Incentive Plan) passed: Adoption of an equity incentive plan involving approximately 15,000,000 shares (15% of fully diluted capital).
- Proposal 7 (Nasdaq Proposal) passed: Approval for issuance of up to 100,000,000 newly issued shares to comply with Nasdaq Listing Rule 5635.
- The company expects to close the transaction in the coming days.
Pono Capital Two, Inc. provided an update regarding its non-redemption agreement with an unaffiliated investor to support its proposed business combination with SBC Medical Group Holdings Incorporated. The filing details the progress of share purchases by the Holder and provides current redemption request data.
🚩 Red Flags
- Ongoing business combination uncertainty: The company faces risks regarding the timely completion or failure of the merger with SBC Medical Group Holdings.
- Redemption risk: While current requests are relatively low (135,471 shares), redemptions remain a critical factor for SPAC-style transactions.
📋 Key Facts
- As of August 21, 2024, the Holder has purchased 1,512,575 shares of Class A common stock at a weighted average price of $11.04 per share.
- Redemption requests received as of 5:00 p.m. ET on August 21, 2024, total 135,471 shares of Class A common stock.
- The non-redemption agreement was originally entered into on January 11, 2024, with subsequent amendments in March and August 2024.
- The purpose of the agreement is to ensure Nasdaq listing approval post-business combination by reducing potential redemptions.
Pono Capital Two, Inc. has entered into Amendment No. 2 to its Non-Redemption Agreement with an unaffiliated investor. This amendment extends the 'Clearance Date' to September 10, 2024, and sets a target date for the completion of its business combination with SBC Medical Group Holdings Incorporated on or before September 16, 2024.
🚩 Red Flags
- Repeated delays/extensions in the timeline for completing the business combination (previously extended from Feb 2024 to Nov 2024, now targeting Sept 2024).
- Risk of redemptions exceeding anticipated levels as noted in forward-looking statements.
- Dependency on SEC review of proxy statements and meeting Nasdaq listing standards post-combination.
📋 Key Facts
- Amendment No. 2 extends the Clearance Date to September 10, 2024.
- The company aims to close the business combination with SBC Medical Group Holdings Inc. by September 16, 2024.
- The original non-redemption agreement involved an investor acquiring 1,500,000 to 1,700,000 shares of Class A common stock in the open market.
- The holder agreed to waive redemption rights and hold shares until after the closing of the business combination.
Pono Capital Two, Inc. has received multiple deficiency notices from Nasdaq regarding three distinct listing requirements: Minimum Market Value of Publicly Held Shares (MVPHS), Total Holders Requirement, and Minimum Public Shares Requirement.
🚩 Red Flags
- Multiple simultaneous delisting threats (MVPHS, Total Holders, and Minimum Public Shares)
- Failure to meet minimum market capitalization threshold ($15M MVPHS)
- Insufficient shareholder base (Total Holders requirement failure)
- Low liquidity/float risk (Minimum Public Shares Requirement failure)
📋 Key Facts
- Received notice on May 6, 2024, for failure to maintain a minimum MVPHS of $15,000,000 per Nasdaq Rule 5450(b)(2)(C).
- The company has until November 4, 2024, to regain compliance with the MVPHS requirement.
- Received notice on May 7, 2024, for failure to maintain a minimum of 400 total holders per Nasdaq Rule 5450(a)(2).
- The company has 45 days to submit a plan to regain compliance with the Total Holders Requirement.
- Received notice on April 2, 2024, for failure to maintain at least 1,100,000 publicly held shares per Nasdaq Rule 5450(b)(2)(B).
- The company must submit a plan to regain compliance with the Minimum Public Shares Requirement by May 17, 2024.
Pono Capital Two, Inc. entered into a Fourth Amendment to its Merger Agreement with SBC Medical Group Holdings Incorporated. The amendment serves solely to extend the transaction's 'Outside Date' to September 30, 2024.
🚩 Red Flags
- Repeated delays: This is the fourth amendment to extend the merger deadline, suggesting difficulty in meeting closing conditions or regulatory requirements.
- Execution risk: The company explicitly notes risks regarding the failure to satisfy conditions and potential redemptions exceeding anticipated levels.
📋 Key Facts
- The amendment extends the Outside Date of the merger to September 30, 2024.
- This is the fourth amendment to the original Merger Agreement (first entered into January 31, 2023).
- The transaction involves a business combination with SBC Medical Group Holdings Incorporated.
- The filing includes an update on the solicitation of proxies for the proposed transaction.
Pono Capital Two, Inc. received a deficiency notice from Nasdaq for failing to meet the Minimum Public Shares Rule (Listing Rule 5450(b)(2)(B)). The company must submit a compliance plan by May 17, 2024.
🚩 Red Flags
- Delisting/Non-compliance notice (Nasdaq Listing Rule 5450(b)(2)(B))
- Failure to maintain minimum public float/shares requirement
📋 Key Facts
- Received written notice from Nasdaq on April 2, 2024.
- Non-compliance with Listing Rule 5450(b)(2)(B) regarding the requirement of at least 1,100,000 publicly held shares.
- Deadline to submit a plan to regain compliance is May 17, 2024.
- Potential for a 180-day extension if Nasdaq accepts the compliance plan.
- The notice is currently a notification of deficiency and does not result in immediate delisting.
Pono Capital Two, Inc. entered into an amendment to its Note Purchase Agreement with SBC Medical Group Holdings Incorporated, increasing the principal amount of a convertible promissory note from $1 million to $2.7 million. This amendment includes mutual releases regarding the termination or failure to consummate their proposed business combination.
🚩 Red Flags
- Significant increase in debt/convertible note principal ($1.7M increase) to facilitate a merger process that has faced potential termination risks.
- The inclusion of mutual releases from claims suggests uncertainty or friction regarding the consummation of the proposed business combination.
📋 Key Facts
- Date of report: February 27, 2024
- Increased Note Principal Amount: From $1,000,000 to $2,700,000
- The amendment includes a release of claims between Pono and SBC regarding the termination or failure of their Merger Agreement.
- The note allows for the conversion of 270,000 shares of Common Stock.
Pono Capital Two, Inc. (a SPAC) successfully held a special meeting where stockholders approved an amendment to extend the deadline for completing a business combination from February 9, 2024, to November 9, 2024. The company also reported significant shareholder redemptions, leaving approximately $17.9 million in the trust account.
🚩 Red Flags
- Significant shareholder redemptions reducing the available capital in the trust account.
- SPAC structure: The need for an extension often indicates difficulty in finding a target or closing a deal within the original timeframe.
📋 Key Facts
- Stockholders approved Proposal 1: Extension of business combination deadline from Feb 9, 2024, to Nov 9, 2024.
- Shareholder redemptions totaled 273,334 shares of Common Stock.
- Remaining trust account balance is approximately $17.9 million following redemptions.
- The Charter Amendment became effective on February 5, 2024.
Pono Capital Two, Inc. is seeking a stockholder vote to extend its deadline for completing a business combination with SBC Medical Group Holdings Incorporated from February 9, 2024, to November 9, 2024. To support this extension and the merger, the company entered into a non-redemption agreement with an investor to acquire 1.5M to 1.7M shares in the open market.
🚩 Red Flags
- SPAC deadline extension indicates potential difficulty in finalizing the merger within the original timeframe.
- Use of non-redemption agreements is a common tactic to prevent massive redemptions that could deplete the trust account, often viewed as a sign of weak shareholder support for the deal structure.
📋 Key Facts
- Proposed deadline extension for business combination: from Feb 9, 2024, to Nov 9, 2024.
- Target company identified as SBC Medical Group Holdings Incorporated.
- Non-redemption agreement entered into with an unaffiliated investor ('Holder').
- Holder to acquire 1,500,000 to 1,700,000 shares of Class A common stock in the open market.
- Incentive mechanism: Holder receives 'Incentive Shares' from Target CEO Yoshiyuki Aikawa upon successful closing if they hold the shares through completion.